How peptide drugs are regulated in the European Union — the EMA centralized procedure, national authorizations, and pharmacovigilance requirements.
Filed under regulation, written for regulator-compliance, founder-operator, pharmacist-compounder, evidence level regulatory-update.
Not medically reviewed. Last updated 2026-04-18. Nothing here is medical advice.
The European Medicines Agency (EMA) plays a central role in regulating peptide-based medicines within the European Union. This article provides an overview of the EU regulatory framework for peptide therapeutics.
Centralized Authorization Procedure
For most innovative peptide medicines, the centralized procedure is used:
Single application to the EMA
Scientific assessment by the Committee for Medicinal Products for Human Use (CHMP)
If approved, marketing authorization valid across all EU/EEA member states
Mandatory for certain product categories (biotech products, orphan medicines)
National Authorization
Some peptide products may be authorized through:
**Mutual Recognition Procedure (MRP)**: Extending a national authorization to other member states
**Decentralized Procedure (DCP)**: Simultaneous application to multiple member states
**National procedure**: Authorization in a single member state
Biosimilar Peptides in the EU
The EU was a pioneer in biosimilar regulation:
First biosimilar approved in EU in 2006 (somatropin biosimilar)
Multiple insulin biosimilars approved
Well-established regulatory pathway for peptide biosimilars
Requires demonstration of biosimilarity through quality, non-clinical, and clinical studies